RIM
BLFS icon

Ranger Investment Management’s BioLife Solutions BLFS Stock Holding History

Ranger Investment Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.14M Sell
269,365
-925
-0.3% -$20.4K 0.37% 74
2025
Q4 		$6.54M Sell
270,290
-19,635
-7% -$514K 0.45% 66
2025
Q3 		$7.4M Buy
289,925
+1,105
+0.4% +$26.2K 0.52% 66
2025
Q2 		$6.22M Sell
288,820
-48,020
-14% -$1.08M 0.43% 64
2025
Q1 		$7.69M Sell
336,840
-770
-0.2% -$20.3K 0.55% 54
2024
Q4 		$8.76M Sell
337,610
-7,460
-2% -$186K 0.55% 54
2024
Q3 		$8.64M Sell
345,070
-39,274
-10% -$928K 0.55% 52
2024
Q2 		$8.24M Buy
384,344
+7,234
+2% +$140K 0.56% 56
2024
Q1 		$7M Buy
377,110
+13,536
+4% +$237K 0.45% 58
2023
Q4 		$5.91M Buy
363,574
+22,906
+7% +$292K 0.36% 62
2023
Q3 		$4.7M Sell
340,668
-19,532
-5% -$308K 0.31% 69
2023
Q2 		$7.96M Buy
360,200
+29,375
+9% +$619K 0.48% 57
2023
Q1 		$7.2M Buy
330,825
+6,535
+2% +$147K 0.48% 52
2022
Q4 		$5.9M Buy
324,290
+7,087
+2% +$146K 0.44% 58
2022
Q3 		$7.22M Sell
317,203
-5,742
-2% -$123K 0.57% 51
2022
Q2 		$4.46M Sell
322,945
-977,462
-75% -$14.3M 0.34% 64
2022
Q1 		$29.6M Buy
1,300,407
+45,147
+4% +$1.19M 1.87% 23
2021
Q4 		$46.8M Buy
1,255,260
+377,358
+43% +$16.2M 2.56% 11
2021
Q3 		$37.2M Sell
877,902
-29,638
-3% -$1.43M 1.98% 17
2021
Q2 		$40.4M Sell
907,540
-14,970
-2% -$527K 2.11% 15
2021
Q1 		$33.2M Sell
922,510
-67,002
-7% -$2.65M 1.83% 24
2020
Q4 		$39.5M Sell
989,512
-144,441
-13% -$4.93M 2.08% 17
2020
Q3 		$32.8M Buy
1,133,953
+671,377
+145% +$14.5M 2.09% 20
2020
Q2 		$7.56M Buy
462,576
+82,224
+22% +$1.13M 0.52% 52
2020
Q1 		$3.61M Buy
380,352
+80,029
+27% +$1.1M 0.32% 61
2019
Q4 		$4.86M Sell
300,323
-7,739
-3% -$126K 0.32% 62
2019
Q3 		$5.12M Buy
308,062
+66,960
+28% +$1.26M 0.37% 60
2019
Q2 		$4.09M Buy
241,102
+43,234
+22% +$754K 0.28% 67
2019
Q1 		$3.54M Buy
197,868
+105,805
+115% +$1.68M 0.26% 68
2018
Q4 		$1.11M Buy
+92,063
New +$1.1M 0.09% 78

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ranger Investment Management's BLFS Position: Q1 2026 in Review

Ranger Investment Management reduced its BioLife Solutions (BLFS) stake by 0.34% in Q1 2026, selling an estimated $20.4K and leaving 269,365 shares worth $5.14M. The position accounts for 0.37% of the portfolio, ranked #74.

Ranger Investment Management first reported a position in BLFS in Q4 2018 and has held it in 30 quarters since. The position peaked at $46.8M in Q4 2021. 187 funds tracked by Wall St. Rank hold BLFS as of Q1 2026.

  • Ranger Investment Management held 269,365 shares of BioLife Solutions worth $5.14M as of Q1 2026.
  • Ranger Investment Management sold 925 BioLife Solutions shares in Q1 2026, an estimated $20.4K.
  • BioLife Solutions made up 0.37% of Ranger Investment Management's portfolio in Q1 2026, its #74 holding.
  • Ranger Investment Management first reported a position in BioLife Solutions in Q4 2018 and has held it in 30 quarters since.
  • Ranger Investment Management's BioLife Solutions position peaked at $46.8M in Q4 2021.
  • 187 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2026.

Based on Ranger Investment Management's 13F filing for Q1 2026, filed 15 May 2026.